Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: biajj & wolf

As usual, you set up a strawman argument. Why were PTSC's revenues SOLELY dependent on licensing revenues from patents which were tied up in USPTO re-exams?

Perhaps that stems from that list of management decisions. For example, were there no companies out there that were ALREADY PROFIT generating that could have been aquired for the money issued in dividends? I personally have 3 friends who were shopping their PROFITABLE companies for less than that amount combined. I don't see PTSC as the victim you seem to perceive them as.

Share
New Message
Please login to post a reply